Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In VitroCharacterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines
Abdulhameed Al‐Ghabkari, Aru Narendran
Cancer Biotherapy and Radiopharmaceuticals (2019) Vol. 34, Iss. 4, pp. 252-257
Closed Access | Times Cited: 18

Showing 18 citing articles:

p21 in Cancer Research
Bahar Shamloo, Sinem Usluer
Cancers (2019) Vol. 11, Iss. 8, pp. 1178-1178
Open Access | Times Cited: 283
Molecular targeting therapies for neuroblastoma: Progress and challenges
Atif Zafar, Wei Wang, Gang Liu, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 2, pp. 961-1021
Open Access | Times Cited: 247
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wei Wang, Najah Albadari, Yi Du, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 3, pp. 414-453
Open Access | Times Cited: 28
Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research
Rishabh Sharma, Jaya Yadav, Sajad Ahmad Bhat, et al.
Molecular Neurobiology (2025)
Closed Access | Times Cited: 1
Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope
Atif Zafar, Wei Wang, Gang Liu, et al.
Cancer Letters (2020) Vol. 496, pp. 16-29
Open Access | Times Cited: 80
Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification
Yan Wang, Fuhao Chu, Jie Lin, et al.
Journal of Ethnopharmacology (2021) Vol. 279, pp. 114399-114399
Closed Access | Times Cited: 59
Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling
Anmol Sharma, Heena Khan, Thakur Gurjeet Singh, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11971-11971
Open Access | Times Cited: 48
Targeting Protein–Protein Interfaces with Peptides: The Contribution of Chemical Combinatorial Peptide Library Approaches
Alessandra Monti, Luigi Vitagliano, Andrea Caporale, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7842-7842
Open Access | Times Cited: 12
Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatment
Magdalena Strachowska, Agnieszka Robaszkiewicz
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108636-108636
Open Access | Times Cited: 4
Decoding the Role of MDM2 as a Potential Ubiquitin E3 Ligase and Identifying the Therapeutic Efficiency of Alkaloids against MDM2 in Combating Glioblastoma
Sudhanshu Sharma, Pravir Kumar
ACS Omega (2023) Vol. 8, Iss. 5, pp. 5072-5087
Open Access | Times Cited: 7
Structure-based designing efficient peptides based on p53 binding site residues to disrupt p53-MDM2/X interaction
Nasim Rasafar, Abolfazl Barzegar, Elnaz Mehdizadeh Aghdam
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 14
Silencing CCNG1 protects MPC-5 cells from high glucose-induced proliferation-inhibition and apoptosis-promotion via MDM2/p53 signaling pathway
Ye Chen, Rui Yan, Bo Li, et al.
International Urology and Nephrology (2020) Vol. 52, Iss. 3, pp. 581-593
Closed Access | Times Cited: 11
Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells in vitro
Abdulhameed Al‐Ghabkari, Aru Narendran
Cancer Biology & Therapy (2021) Vol. 22, Iss. 4, pp. 333-344
Open Access | Times Cited: 10
Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action
Wei Wang, Xinjie Wang, Mehrdad Rajaei, et al.
Cancers (2020) Vol. 12, Iss. 12, pp. 3651-3651
Open Access | Times Cited: 9
p53-Mediated Radiosensitization of 177Lu-DOTATATE in Neuroblastoma Tumor Spheroids
Sara Lundsten, Hanna Berglund, Preeti Jha, et al.
Biomolecules (2021) Vol. 11, Iss. 11, pp. 1695-1695
Open Access | Times Cited: 9
Promising Molecular Targets and Novel Therapeutic Approaches in Neuroblastoma
Xu Yang, Jixia Li, Jigang Yang
Current Pharmacology Reports (2022) Vol. 9, Iss. 1, pp. 43-58
Open Access | Times Cited: 4
p53 and the E3 Ubiquitin Ligase MDM2 in Glaucomatous Lamina Cribrosa Cells
Kealan McElhinney, Mustapha Irnaten, Jeffrey O’Callaghan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 12173-12173
Open Access
Implications of ubiquitination and the maintenance of replication fork stability in cancer therapy
Donghui Xia, Xuefei Zhu, Ying Wang, et al.
Bioscience Reports (2023) Vol. 43, Iss. 10
Open Access | Times Cited: 1
Page 1

Scroll to top